Nayak Debadatta, Chadha Vishal, Jain Shruti, Nim Priyanka, Sachdeva Jyoti, Sachdeva Garima, Vivekanand Kumar, Khurana Anil, Raheja Sunil M, Manchanda Raj K
Epidemic Cell, Central Council for Research in Homoeopathy, New Delhi, Delhi, India.
Dr. Hedgewar Aarogya Sansthan, New Delhi, Delhi, India.
Homeopathy. 2019 Aug;108(3):150-157. doi: 10.1055/s-0038-1676953. Epub 2019 Mar 5.
Dengue is an emerging threat to public health. At present, no clear modalities are available for the prevention and management of thrombocytopenia due to dengue. This article reports the clinical outcomes of integrative homeopathic care in a hospital setting during a severe outbreak of dengue in New Delhi, India, during the period September to December 2015.
Based on preference, 138 patients received a homeopathic medicine along with usual care (H+UC), and 145 patients received usual care (UC) alone. Assessment of thrombocytopenia (platelet count < 100,000/mm) was the main outcome measure. Kaplan-Meier analysis enabled comparison of the time taken to reach a platelet count of 100,000/mm.
There was a statistically significantly greater rise in platelet count on day 1 of follow-up in the H+UC group compared with UC alone (mean difference = 12,337; 95% confidence interval [CI], 5,421 to 19,252; = 0.001). This trend persisted until day 5 (mean difference = 14,809; 95% CI, 1,615 to 28,004; = 0.02). The time taken to reach a platelet count of 100,000/mm was nearly 2 days earlier in the H+UC group compared with UC alone (H+UC: 3.44 days ± standard error of the mean [SEM] 0.18; 95% CI, 3.08 to 3.80; UC: 5.28 days ± SEM 0.29; 95% CI, 4.71 to 5.86; < 0.001).
These results suggest a positive role of adjuvant homeopathy in thrombocytopenia due to dengue. Randomized controlled trials may be conducted to obtain more insight into the comparative effectiveness of this integrative approach.
